Clinical trial
Study of Sequential Topoisomerase, Irinotecan/Oxaliplatin - Etoposide…
NCT00240097 · University of Alabama at Birmingham, Other · Completed
Key facts
| NCT number | NCT00240097 |
|---|---|
| Title | Study of Sequential Topoisomerase, Irinotecan/Oxaliplatin - Etoposide /Carboplatin in Extensive Small Cell Lung Cancer (SCLC) |
| Official title | Study of Sequential Topoisomerase, Irinotecan/Oxaliplatin-Etoposide/Carboplatin in Extensive SCLC |
| Lead sponsor | University of Alabama at Birmingham, Other |
| Collaborators | Sanofi-Synthelabo Industry Amgen |
| Status | Completed |
| Phase | Phase 2 |
| Study type | Interventional |
| Conditions | Non-Small Cell Lung Cancer |
| Intervention type | Drug |
| Interventions | Intervention A: Irinotecan, Oxaliplatin, Neulasta, Intervention B: Etoposide, Carboplatin |
| Enrollment | 30 |
| Start date | Jun 1, 2005 |
| Primary completion | Jun 1, 2010 |
| Completion | Jun 1, 2010 |
| First posted | Oct 17, 2005 |
| Last update posted | Nov 27, 2014 |
| Countries | United States |
At a glance
- 1–9 Study sites
- Yes Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: